TNT to Increase the Clinical Complete Response Rate for Distal LARC — TESS  

Rectal Cancer Clinical Trial

Official title: Total Neoadjuvant trEatment to Increase the Clinical Complete reSponse Rate for diStal Locally Advanced Rectal Cancer (TESS)

Status Active, not recruiting

Clinical Trial Summary

This is a open-label, single-arm study to investigate the safety and efficacy of total neoadjuvant treatment (TNT) in patients with locally advanced resectable rectal cancer.

Clinical Trial Description

Standard treatment of rectal cancer is neoadjuvant capecitabine chemotherapy with radiotherapy, followed by total mesorectal excision.

A new concept suggests organ preservation as an alternative to rectal excision in good responders after neoadjuvant radiochemotherapy to decrease surgical morbidity and increase quality of life.

The rational is the fact that 15%-20% of patients have sterilized tumours after chemoradiotherpay for locally advanced rectal cancer. As compared to capecitabine alone, oxaliplatin and more intensified chemotherapy have been shown to increase tumor regression in the neoadjuvant chemoradiation setting. Meanwhile, prolong of time interval from the end of radiotherapy to assessment of tumor response could further increase pathologic complete response rate and complete clinical response rate.

The objective of this trial is to increase the rate of clinical complete response for distal rectal cancer patients by optimizing tumour response. The investigators expect to increase chance of clinical complete response by using total neoadjuvant treatment regimen as compared to conventional chemoradiotherapy alone. ;

Related Conditions & MeSH terms

• Chemoradiation
• Rectal Cancer
• Rectal Cancer Stage II
• Rectal Cancer Stage III
• Rectal Neoplasms

• NCT number: NCT03840239
• Study type: Interventional
• Source: Sun Yat-sen University
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: December 25, 2018
• Completion date: June 30, 2027